(NASDAQ: ASND) Ascendis Pharma A's forecast annual revenue growth rate of 55.27% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 49.66%, and it is also forecast to beat the US market's average forecast revenue growth rate of 11.63%.
Ascendis Pharma A's revenue in 2025 is $348,326,595.On average, 7 Wall Street analysts forecast ASND's revenue for 2025 to be $31,636,485,125, with the lowest ASND revenue forecast at $26,780,974,727, and the highest ASND revenue forecast at $44,761,118,227. On average, 7 Wall Street analysts forecast ASND's revenue for 2026 to be $55,414,786,210, with the lowest ASND revenue forecast at $42,432,886,339, and the highest ASND revenue forecast at $75,775,919,562.
In 2027, ASND is forecast to generate $72,711,943,459 in revenue, with the lowest revenue forecast at $70,215,115,469 and the highest revenue forecast at $75,456,504,498.